Events
July 9, 2021
Mid Year summary | to the past, to present, to the future!
Summarizing the past and looking forward to the future, Quacell will gradually realize the sustainable development vision in the future！
Learn More
News
June 25, 2021
Dr. Poon, CEO of QuaCell Biotechnology, Co., Ltd. was honored to be elected Associate Editor of RE: GEN Open
June 25, 2021 / Quacell Newsroom /- Dr. Poon, CEO of Quacell Biotechnology Co., Ltd. was invited by Re: Gen Open to be selected as Associate Editor.
Learn More
News
May 22, 2021
Conclusion | Biofuture2021
The two-day Biofuture 2021 Next Generation Antibody Drug Technology Innovation Conference & Cell and Gene Therapy Innovation Conference came to a successful conclusion.
Learn More
News
May 21, 2021
BIG EVENETS. Day 2 | Biofuture 2021
Quacell Biotechnology will continue to show you more latest information about our products in the #B21 booth
Learn More
News
May 20, 2021
BIG EVENETS. Day 1 | Biofuture 2021
Biofuture 2021 Next Generation Antibody Drug Technology Innovation Conference & Cell and Gene Therapy Innovation Conference held in Crowne Plaza Shanghai Jiangong Pujiang Hotel
Learn More
News
April 30, 2021
China Medical System company(CMS) visited Quacell Biotechnology
Mr Lin Gang, Chairman of the Board of Directors of CMS Co., Ltd., Mr Wang Gang, General Manager of CMS Health Fund, and Mr Zhou Haiyang, Deputy General Manager, visited QuaCell Biotechnology Co., Ltd. (Quacell Biotechnology) and for investigation.
Learn More
News
April 27, 2021
Mr. Wei Jiang, Director of Zhongshan Customs and his delegation visited Quacell biotechnology for investigation
Learn More
Events
April 16, 2021
Third anniversary | the 3rd anniversary celebration for QuaCell Biotechnology
Happy birthday to QuaCell !! With the splendid completion of the new building, we ushered in the grand celebration of the third anniversary！
Learn More
News
March 9, 2021
OBiO and QuaCell Biotechnology reached a strategic cooperation on the joint development of the Wayne293™ host cell platform and high-toxin-producing derivative cell lines
On March 9, 2021, OBiO and QuaCell Biotechnology jointly announced a strategic cooperation intent on the joint development of the Wayne293™ host cell platform and high-toxin-producing derivative cell lines. This cooperation aims to complement each other's technological advantages, connect upstream and downstream, and provide more comprehensive, high-quality and efficient technical services and solutions to cell and gene therapy customers around the world.
Learn More
News
January 25, 2021
QuaCell Biotechnology's Notice on Strengthening the Disinfection of Product Packaging before Shipment
QuaCell Biotechnology implements temporary outer packaging disinfection measures to deliver the full line of cell culture media, culture supplement products, and technical service deliveries.
Learn More